Anti-NCX1 (SLC8A1) Antibody

Ca²⁺ has proven to be a universal signaling molecule in excitable and non-excitable cells. However, being that its intracellular concentration is 1000 times lower than that of the extracellular milieu, it is important for the cell to keep this ratio for proper function. NCX, a Na⁺/Ca²⁺ exchanger is responsible for most of the efflux of Ca²⁺ from the cell^1-3. The NCX transporter is a member of the SLC8 family of solute carriers which in turn belong to the CaCA superfamily^1,4,5.

NCX-1 is one of three Na⁺/Ca²⁺ exchangers (NCX-1, NCX-2, NCX-3) leading to one Ca²⁺ movement across the plasma membrane in exchange of three Na⁺ influx. However, the transporter can reverse the direction of the transport if the concentrations of Na⁺ and Ca²⁺ change⁶. The transporter has nine transmembrane domains and intracellular N- and C-terminals. Between tansmembrane domains 5 and 6, the presence of an extra-long intracellular loop, termed the f-loop, is responsible for regulating the activity of NCX-1 via several different mechanisms like ion binding, phosphorylation, etc. The f-loop also has sites which undergo alternative splicing⁷.

Of the three NCX expressed in mammalian cells, NCX-1 is the most widely expressed. Its expression is detected in the heart, brain, and kidney. NCX-1 undergoes alternative splicing in a tissue-dependent manner. The first splice region does not change the overall structure of the protein but rather enables the expression of the gene specific to the tissues which require the expression of the gene. The second splicing site leads to a number of proteins varying in length. NCX-2 expression is much more limited; it is expressed only in neurons. NCX-3 is expressed in skeletal muscle and in some regions of the brain and undergoes alternative splicing in a similar fashion to that of NCX-1^1,8.

Due to its central role in modulating Ca²⁺ levels in the cell, NCX-1 has become a pharmaceutical target in the development of drugs for various heart diseases and neurological disorders¹.